APA (7th ed.) Citation

Itzykson, R., Thepot, S., Beyne-Rauzy, O., Ame, S., Isnard, F., Salanoubat, C., . . . Fenaux, P. (2011). 174 Does addition of erythropoietic stimulating agents (ESAs) improve the outcome of higher-risk MDS patients treated with azacitidine (AZA)? Leukemia Research, 35, S68. https://doi.org/10.1016/S0145-2126(11)70176-X

Chicago Style (17th ed.) Citation

Itzykson, R., et al. "174 Does Addition of Erythropoietic Stimulating Agents (ESAs) Improve the Outcome of Higher-risk MDS Patients Treated with Azacitidine (AZA)?" Leukemia Research 35 (2011): S68. https://doi.org/10.1016/S0145-2126(11)70176-X.

MLA (9th ed.) Citation

Itzykson, R., et al. "174 Does Addition of Erythropoietic Stimulating Agents (ESAs) Improve the Outcome of Higher-risk MDS Patients Treated with Azacitidine (AZA)?" Leukemia Research, vol. 35, 2011, p. S68, https://doi.org/10.1016/S0145-2126(11)70176-X.